New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
08:20 EDTMRKMerck allergy drug studies met CBER test of meaningful difference, FDA staff say
In briefing documents ahead of the Allergenic Products Advisory Committee meeting scheduled for January 28 to review the Biologics License Application for Merck's Ragwitek sublingual tablet for oral use, FDA staff wrote that studies P05233 and P05234 "met the sponsorís pre-defined criterion for success of a difference in average TCS of -1.80 over the peak ragweed pollen season...In addition, the two studies met CBERís assessment of meaningful differences for allergen immunotherapy." The document also notes that none of the adverse events categorized as serious by investigators or Merck in the studies were considered related to the study drug and that there were no deaths in any of the five clinical development trials of Ragwitek. Reference Link
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
08:33 EDTMRKFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
April 13, 2015
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
April 9, 2015
09:25 EDTMRKPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
07:14 EDTMRKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use